Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02862405
Other study ID # RC-P009
Secondary ID
Status Completed
Phase N/A
First received August 2, 2016
Last updated August 8, 2016
Start date March 2011
Est. completion date March 2015

Study information

Verified date August 2016
Source Lille Catholic University
Contact n/a
Is FDA regulated No
Health authority France: Ministry of Health
Study type Observational

Clinical Trial Summary

The loss of central vision causes difficulty not only in reading but also in faces recognition, and in particular in the identification of facial expression, objects or spaces. These visual deficits have been mainly studied in relation with reading, which is the main complaint of these kind of patients. However, there are not enough data regarding perception of objects and spaces in this population. Then, the objectives are to study the visual-spatial abilities in individuals with vision loss, and altered cognitive processes, (2) to develop clinics tools for early detection and quantification of visual-spatial deficits and (3)to understand the capacities of normal peripheral vision in order to test the possibility of potential training for use of peripheral vision when central vision is impaired by an ophthalmic pathology.


Recruitment information / eligibility

Status Completed
Enrollment 260
Est. completion date March 2015
Est. primary completion date March 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria cases:

- Patients with eye disease causing loss of central or peripheral vision

- French speakers

- Age between 18 and 90 years old

- Written consent

- Health insurance

Inclusion Criteria controls:

- Sex and age matched controls (+/- 5 years)

- French speakers

- Normal visual examination with visual acuity of min 9/10

Exclusion Criteria:

- Psychiatric disease or neurological pathologies

- Communication difficulties (deafness / mutism)

- Drug treatment altering concentration

- Mental deterioration with MMS <24

- Alcoholism or addiction to drugs

- Persons under guardianship

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional


Related Conditions & MeSH terms


Intervention

Other:
vision tests


Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Lille Catholic University University Hospital, Lille

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison of performances in visual tests between different groups according to error rate These behavioral studies include a series of short tests of 5 to 10 minutes each (not exceeding 60 minutes with breaks and instructions) in which photos of scenes or isolated objects will be presented in central or peripheral vision using a computer screen or a panoramic screen covering a 180° field. at inclusion No
Primary Comparison of performances in visual tests between different groups according to answer time These behavioral studies include a series of short tests of 5 to 10 minutes each (not exceeding 60 minutes with breaks and instructions) in which photos of scenes or isolated objects will be presented in central or peripheral vision using a computer screen or a panoramic screen covering a 180° field. at inclusion No
Secondary Estimation of the score of visual acuity by the logMAR chart at inclusion No
Secondary Measure of lesion size at inclusion No
Secondary Pearson correlation coefficient to determine the correlation between the performance parameters during visual tests (error rate and answer time) and clinical parameters (visual acuity and lesion size) These behavioral studies include a series of short tests of 5 to 10 minutes each (not exceeding 60 minutes with breaks and instructions) in which photos of scenes or isolated objects will be presented in central or peripheral vision using a computer screen or a panoramic screen covering a 180° field. at inclusion No
See also
  Status Clinical Trial Phase
Completed NCT01598818 - First-Sight Refractive Error Correction in the Developing World
Completed NCT01838655 - Nitisinone for Type 1B Oculocutaneous Albinism Phase 1/Phase 2